Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Capital Employed (2016 - 2025)

Cytosorbents' Return on Capital Employed history spans 14 years, with the latest figure at 0.05% for Q4 2025.

  • Quarterly results put Return on Capital Employed at 0.05% for Q4 2025, up 38.0% from a year ago — trailing twelve months through Dec 2025 was 0.05% (up 38.0% YoY), and the annual figure for FY2025 was 0.05%, up 36.0%.
  • Return on Capital Employed for Q4 2025 was 0.05% at Cytosorbents, up from 0.37% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.05% in Q4 2025 to a low of 0.86% in Q4 2023.
  • The 5-year median for Return on Capital Employed is 0.45% (2022), against an average of 0.46%.
  • The sharpest move saw Return on Capital Employed soared 57bps in 2021, then crashed -43bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.29% in 2021, then crashed by -105bps to 0.59% in 2022, then tumbled by -45bps to 0.86% in 2023, then skyrocketed by 49bps to 0.44% in 2024, then skyrocketed by 88bps to 0.05% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.05%, 0.37%, and 0.4% for Q4 2025, Q3 2025, and Q2 2025 respectively.